A new breast cancer treatment, capivasertib (also known as Truqap), has been approved for use on the NHS in England and Wales, offering renewed hope for patients with advanced hormone receptor-positive, HER2-negative breast cancer. Developed by AstraZeneca, this twice-daily pill targets the AKT protein, which plays a key role in cancer cell growth. Clinical trials have shown that when combined with the hormone therapy fulvestrant, capivasertib can extend the time before disease progression from 3.1 to 7.3 months, particularly benefiting patients with specific genetic mutations such as PIK3CA, AKT1, or PTEN .
The approval of capivasertib follows extensive research by the Institute of Cancer Research in London and is considered a significant advancement in personalized cancer treatment. It is expected to benefit up to 3,000 women annually, especially those whose cancer has become resistant to existing treatments. Healthcare experts emphasize the importance of rapid genetic testing to identify eligible patients promptly, ensuring timely access to this innovative therapy . Click for More Details
